Stock EXEL EXELIXIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Exelixis, Inc.

Equities

EXEL

US30161Q1040

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/05/2024 BST 		5-day change 1st Jan Change
21.92 USD -6.54% Intraday chart for Exelixis, Inc. -7.53% -8.61%
05-01 RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept MT
04-30 Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Exelixis: Q1 Earnings Snapshot
AQ
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
BU
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
BU
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
BU
BioInvent International AB Year-end report January 1, December 31, 2023
AQ
BioInvent International AB Year-end report January 1 – December 31, 2023
AQ
Exelixis: Q4 Earnings Snapshot
AQ
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
BU
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
BU
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
BU
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
BU
Bristol Myers Squibb - Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits after Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
AQ
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX Tablets
AQ
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
BU
BioInvent regains rights to immuno-oncology targets from Exelixis
AQ
BioInvent regains rights to immuno-oncology targets from Exelixis
AQ
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
BU
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
BU
Exelixis 2023 R&D Day, Science and Strategy to be Webcast on December 12, 2023
AQ
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EXEL Stock
  4. News Exelixis, Inc.
  5. Press Releases